Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Price Down 5.6% – Should You Sell?

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report)’s share price traded down 5.6% during trading on Tuesday. The stock traded as low as $12.35 and last traded at $12.60. 6,393 shares traded hands during trading, a decline of 96% from the average daily volume of 145,575 shares. The stock had previously closed at $13.35.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on FSNUY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Get Fresenius SE & Co. alerts:

View Our Latest Report on FSNUY

Fresenius SE & Co. Stock Performance

The firm has a market cap of $28.11 billion, a price-to-earnings ratio of 15.79 and a beta of 0.62. The firm’s 50 day moving average is $13.18 and its 200-day moving average is $12.42. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. Sell-side analysts anticipate that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.

Featured Articles

• Five stocks we like better than Fresenius SE & Co.
• 5 Stocks Showing Why Pricing Power Matters More Than Government Money
• Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
• NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
• Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown

Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.